Estrogen-regulated cut-off values of ps2 and cathepsin d expression in breast carcinomas

Advances in Experimental Medicine and Biology

Volumn 617, Issue , 2008, Pages 341-348

  Markićević, Milan ^a   Petrović, Aleksandra ^a   Kanjer, Ksenija ^a   Nešković Konstantinović, Zora ^a   Nikolić Vukosavljević, Dragica ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN PS2; TFF1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

BREAST CARCINOMA; CANCER GRADING; CANCER GROWTH; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME REGULATION; FEMALE; HISTOPATHOLOGIC SKIN REACTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ARTICLE; BREAST TUMOR; CANCER STAGING; DRUG EFFECT; GENE EXPRESSION REGULATION; LYMPH NODE; MENOPAUSE; METABOLISM; PATHOLOGY; PROGNOSIS;

EQUUS ASINUS;

BREAST NEOPLASMS; CATHEPSIN D; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPH NODES; MENOPAUSE; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 46749158342     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-69080-3_32     Document Type: Conference Paper

References (21)

1. National Institutes of Health Consensus Development Conference Statement (2001) Adjuvant therapy for BC, November 1-3, 2000. J Natl Cancer Inst 93:979-989.
2. Stack G, Kumar V, Green S, et al. (1988) Structure and function of the pS2 gene and estrogen receptor in human BC cells. In: Lippmann ME, Dickson RB, editors. BC. Cellular and molecular biology. Boston: Kluwer, pp. 185-206.
3. Giamarchi C, Solanas M, Chailleux C, et al. (1999) Chromatin structure of the regulatory regions of pS2 and cathepsin D genes in hormone-dependent and -independent BC cell lines. Oncogene 18:533-541.
4. Gillesby BE, Zacharewski TR (1999) pS2 (TTF1) levels in human BC tumor samples: correlation with clinical and histological prognostic markers. Breast Cancer Res Treat 56:253-265.
5. Thompson AM, Hawkins RA, Elton RA, et al. (1993) pS2 is an independent factor of good prognosis in primary BC. Br J Cancer 68:93-96.
6. Foekens JA, van Putten WLJ, Portengen H, et al. (1993) Prognostic value of pS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. J Clin Oncol 11:899-908.
7. Barett AJ (1970) Cathepsin D: purification of isoenzymes from human and chicken liver. Biochem J 117:601-607.
8. Richo G, Conner GE (1991) Proteolytic activation of human procathepsin D. Adv Exp Med Biol 306:289-296.
9. Cavailles V, Augereau P, Rochefort H (1993) Cathepsin D gene is controlled by a mixed promoter, and estrogens stimulate only TATA-dependent transcription in BC cells. Proc Natl Acad Sci 90:203-207.
10. Westley BR, May FE (1987) Oestrogen regulates cathepsin D mRNA levels in oestrogen responsive human BC cells. Nucl Acids Res 15:3773-3786.
11. Briozzo P, Morisset M, Capony F, et al. (1988) In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by BC cells. Cancer Res 48:3688-3692.
12. Liaudet-Coopman E, Beaujouin M, Derocq D (2006) Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett 237:167-179.
13. Foekens JA, Look MP, Bolt-de-Vries J, et al. (1999) Cathepsin-D in primary BC: prognostic evaluation involving 2810 patients. Br J Cancer 79:300-307
14. Fitzgibbons PL, Page DL, Weaver D, et al. (2000) Prognostic factors in BC. College of American Pathologist Consensus Statement 1999. Arch Pathol Lab Med 124:966-978.
15. Wittliff JL, Pasic R, Bland KI (1991) Steroid and peptide hormone receptors identified in breast tissue. In: Bland KI, Copelano EM, editors. The breast: comprehensive management of benign and malignant disease. Philadelphia: WB Saunders, pp. 900-936.
16. Gion M, Mione R, Dittadi R, et al. (1995) Relationship between cathepsin D and other pathological and biological parameters in 1752 patients with primary BC. Eur J Cancer 31A:671-677.
17. Bolufer P, Torregrosa MD, Gomez L, et al. (1996) Specific oncological contribution of cathepsin D and pS2 in human BC: their relationship with TNM status, estradiol receptors, epidermal growth factor receptor and neu amplification. Clin Chim Acta 274:89-103.
18. Gillesby BE, Zacharewski TR (1999) pS2 (TTF1) levels in human BC tumor samples: correlation with clinical and histological prognostic markers. Breast Cancer Res Treat 56:253-265.
19. Nikolić-Vukosavljević D, Grujić-Adanja G, Janković R, et al. (1998) pS2 in breast carcinomas: association with steroid hormone receptor status. Tumori 84:691-694.
20. Nikolić-Vukosavljević D, Grujić-Adanja G, Janković R (2001) pS2 protein in breast carcinomas: cut-off value of estrogen-regulated expression. Neoplasma 48:1-6.
21. Nikolić-Vukosavljević D, Grujić-Adanja G, Nastić-Mirić D (1998) Cathepsin D: association between TN-stage and steroid receptor status of breast carcinoma. Tumor Biol 19:329-334.